Carotid Artery Stenting With Cilostazol Addition for Restenosis
Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
CAS-CARE study was conducted to evaluate the inhibitory effect of cilostazol, compared to
that of other antiplatelet drugs, on in-stent restenosis following carotid artery stenting
(CAS) in patients scheduled to undergo CAS. Study design is Multicenter Prospective
Ranodomized Controlled Study, rondomized by cilostazol/non-cilostazol group prior to CAS. 900
patients will be enrolled for 2 years and followed 2 years with in-stent restenosis after
CAS, evaluated by carotid ultrasound and angiography.
Phase:
N/A
Details
Lead Sponsor:
Kobe City General Hospital
Collaborators:
Chiba University Foundation for Biomedical Research and Innovation Fukuoka University Kobe University Kyoto University Mie University Nagasaki University Nagoya University Okayama University Osaka University Wakayama Medical University Yamaguchi University Hospital